Introduction
Dyspepsia is a very common set of clinical symptoms. Clear-cut scientific evidence of the effectiveness of diag nostic schemes is unavailable for most clinical situations related to dyspepsia. For this and other reasons, practice patterns vary widely. The development of explicit detailed criteria of appropriateness of use of endoscopy is an at tempt to produce best available evidence (based on a vali dated panel process and expert judgment) where better evi dence is lacking, with the aim to assist the clinician in dai ly decision making.
In November 1998, a multidisciplinary European expert panel convened in Lausanne, Switzerland, to discuss and develop criteria for the appropriate use of gastrointestinal endoscopy, a widely-used procedure, regarded as highly ac curate and safe. The RAND appropriateness method was chosen for this purpose, because it allows the development of appropriateness criteria based on published evidence and supplemented by explicit expert opinion. A detailed de scription of the RAND appropriateness method, including the literature search process [1] , and of the whole process, as well as the global results of the panel [2] , are published as separate articles in this issue of the Journal. The litera ture review was based on a systematic search of Medline, Embase and the Cochrane Library conducted up to the end of 1997 and completed with some key articles published in 1998. Updating and revision of the literature review is cur rently ongoing.
This article presents a literature review on dyspepsia, that was provided to the panelists to study and comment prior to the panel meeting to support their ratings of appropriate ness of use of upper gastrointestinal endoscopy. This article furthermore presents an overview of the main panel results related to dyspepsia and a summary of published evidence and panel-based appropriateness criteria.
Literature Review

Definition of Dyspepsia
Evaluation of dyspepsia is reportedly the most frequent in dication for upper endoscopy referrals [3] . Although com monly used by clinicians, the term dyspepsia has not been uniformly defined, thus complicating the critical review of the literature relating dyspepsia to patient outcome. To per mit standardisation of terminology and a better understand ing of dyspepsia, a 1988 working group [4] established the following classification: Dyspepsia is either organic (that is, due to specific lesions such as peptic ulcer, esophagitis, gastric carcinoma or other pathologies) or non-organic (up per abdominal discomfort for which no focal lesion is responsible). Four dyspepsia sub-groups were defined, based on predominant symptoms and potential etiologies [4, 5] : ulcer-like, reflux-like, dysmotility-like, non-specific. An international working party consensus [6] defined dys pepsia as episodic or persistent abdominal symptoms, often related to food intake, which patients or physicians believe to be due to disorders of the proximal portion of the diges tive tract. At the Maastricht consensus conference in 1997, a workshop on dyspepsia [7] adopted the following defini tion of dyspepsia: pain or discomfort in the upper abdo men, including nausea, vomiting, early satiety, epigastric fullness and regurgitation but not heartburn or dysphagia.
The development of a reliable tool providing a global measurement scale for severity of dyspepsia is a difficult task, due to the difficulty in defining dyspepsia uniformly. The Glasgow dyspepsia severity score, a global measure ment scale for dyspepsia, seems to be a valid, reproducible tool but no definition of dyspepsia is given and no distinc tion is made between the different forms of dyspepsia [8] . (63) 807 (25) 359 (23) 630 (28) Gastritis/erosions 0(0) 16 (5) 0(0) 1214 (38) 757 (47) 783 (35) Duodenitis 9(2) 17(6) 12 (10) 430 (1 3) 214 (13) 328 (14) Gastric ulcer 17 (4) 17 (6) 4(3) 1 1 9 (4) 55 (3) 35 (2)
Duodenal ulcer 34 (9) 25 (8) 15 (13) 474 (1 5 A severity questionnaire of the eight most frequently oc curring and most severe symptoms of dyspepsia has recent ly been validated for research purposes [9] .
Symptom pattern has a poor predictive value for the under lying cause of dyspepsia (see sub-chapter 1.4), and we have thus elected to group patients with upper abdominal symptoms as defined above, using the term "dyspepsia" in the indication matrix. This summary specifically refers to uncomplicated dyspeptic symptoms and the average-risk patient. Patients with weight loss, anemia, evidence of gas trointestinal bleeding, obstruction, dysphagia or odynopha gia, immunodeficiency or other systemic illnesses are not considered to be typical patients in the context of the sum mary which follows. Furthermore, patients presenting with isolated heartburn or regurgitation are discussed in a sepa rate article on GERD in this issue of the Journal [10] .
Occurrence of Dyspepsia
The prevalence of dyspeptic symptoms in the general pop ulation is estimated to be 14 to 41 % [7,11 -13] , with geo graphical differences in the prevalence of dyspepsia, for example between Sweden (19%) and England (41%) [14] . Population surveys suggest that about 25 % of patients with dyspepsia seek medical attention [12, 15] . The prevalence of dyspepsia is characterised by an important turnover when measuring onset and disappearance rates [11] . Johnsen et al. examined the association between dyspeptic symptoms and endoscopic and histological diagnoses. With the exceptions of peptic ulcer disease and endoscopic duo denitis, they found no association of clinical value [16] .
Etiology of Dyspepsia
Among random dyspeptic patients, endoscopy is consid ered normal in 25 to 76% [17] [18] [19] [20] [21] [22] [23] [24] [25] . Table 1 shows the prevalence of endoscopic changes in dyspeptic patients (combined results of five European prospective studies in cluding 7,853 patients).
Many gastroenterologists and pathologists have come to realise that endoscopic appearances frequently do not pre dict histological alterations. Gastric biopsy is therefore an essential part of routine endoscopic examination regardless of the macroscopic appearance of the mucosa [26] .
Increasing age is related to higher frequency of organic disease in dyspeptic patients [17, 20, 21, [27] [28] [29] [30] , Cancer is rarely found in patients below 45 years of age. Helicobacter status has a significant influence on the prev alence of organic disease at endoscopy in patients with dyspepsia. Most gastric and duodenal ulcers, and most gas tric cancers are thus associated with a positive Helicobac ter status; erosive and non-erosive gastritis as well as duo denitis are significantly more frequent in Helicobacter-positive than in Helicobacter-negative patients, whereas the frequency of esophagitis does not seem to be different be tween the two groups. Table 3 shows the prevalence of or ganic disease in dyspeptic patients with respect to HP sta tus (combined results [17] [18] [19] , including a total of 1.964 patients).
Predictive
Value of Symptoms for Organic Diagnosis in Dyspepsia
The classification of ulcer-like, reflux-like, dysmotilitvlike, non-specific symptoms was first formally tested b\ Talley [23] . In a prospective evaluation of 820 outpatients referred for endoscopy, 31 % of patients fitted into more than one historical dyspepsia subgroup, and 27 had non specific symptoms that could not be classified. Symptom?, alone were not found to be sensitive in differentiating pa tients with organic disease from patients with non-organic symptoms. These findings were confirmed in other studies [21, [31] [32] [33] . Dysmotility-like dyspepsia was found to re sult more often in a negative endoscopy [21] . There was no predictive value as regards the patients' predictions of their own diagnoses [32] . In a simulation study of three dyspeptic symptom complexes performed with general practitioners, it was recently found that there is a consider-Downloaded by: Bibliothèque Cantonale et Universitaire. Copyrighted material. Normal  66  73  188  61  1 52  37  478  26  613  29  553  21   Gastritis/erosions  0  0  0  0  80  19  703  38  788  38  1 183  44   Duodenitis  1  1  8  3  75  18  253  14  290  14  354  1 3   Gastric ulcer  1  1  16  5  1 1  3  24  1  45  2  129  5   Duodenal ulcer  3  3  31  10  51  12  59  3  280  13  349  13   Gastric cancer/  0  0  9  3  0  0  45  2  2  0 able variation in the reliability with which different symp toms are reported [34] , which may partially explain the in ability of conventional history-taking to identify the cause of dyspepsia.
Appropriate preliminary screening of patients with acute dyspepsia can separate a group at low risk who will require investigations only if their symptoms do not resolve from a group at high risk requiring urgent outpatient consultations [35] . Numans et al. found that pain on an empty stomach, absence of pain after a meal, together with age, sex, infor mation on former dyspeptic diseases, medication and smoking could predict peptic ulcer with an AUC (area un der the curve) of 0.78 [36] . In the study of Muris et al. higher age, male sex, pain at night, relief by antacids or food and previous history of peptic ulcer disease were identified as predictors of organic cause for abdominal symptoms [37] .
Helicobacter pylori in Dyspepsia
Prevalence/Incidence of Helicobacter pylori Helicobacter pylori is found in 10 to 52% of asymptomatic individuals [8, [38] [39] [40] [41] [42] . The prevalence of HP increases with age but is not correlated with gender [39] [40] [41] . With the advent of improved living conditions, the incidence of HP infection has probably decreased over the generations [43, 44] .
Relationship between Helicobacter pylori and Peptic Ulcer Disease (PUD)
Various investigators have documented H. pylori infection in 90 to 100% of patients with duodenal ulcers and 70 to 90% of patients with gastric ulcers [45] [46] [47] . In patients with duodenal ulcers, Helicobacter eradication results in long-lasting remission. At one year, ulcers had recurred in 2 % of antibiotic-treated patients compared to 85 % of un treated patients [48] . H. pylori treatment has also been shown to be effective in preventing recurrence of gastric ulcers. One study documented a 2-year recurrence rate of 13% in patients with gastric ulcers randomised to treat ment with triple antibiotic therapy, compared to 74% of the group treated with ranitidine only [45] .
Relationship between Helicobacter pylori and Non-Ulcer Dyspepsia (NUD)
In contrast to gastroduodenal ulcer disease, gastric malig nancy and proven gastritis, there is still a lack of convin cing evidence of a causal relationship between Helicobac ter pylori and NUD [7, 49] . Most studies thus did not re port a significant difference in symptoms between Helicobacter-positive and Helicobacter-negative patients with non-ulcer dyspepsia [50] [51] [52] . A recent French consensus conference summarised the results of 15 studies which at tempted to establish a causal link between HP infection and dyspepsia [53] : the level of evidence for such an asso-Downloaded by: Bibliothèque Cantonale et Universitaire. Copyrighted material.
ciation is poor. A recent meta-analysis of HP prevalence rates in NUD and asymptomatic control patients indicates that prevalence is greater in patients with NUD than in the controls (difference 23%) [54] . The studies analysed were, however, heterogeneous and the definition of dyspep sia was not standardised, making comparisons difficult.
Studies evaluating the impact of eradication treatment in NUD have not yielded convincing results. Almost all stud ies showed major methodological flaws, including small sample size, lack of long-term follow-up and use of ill-de fined outcome measures. Some of these studies have shown improvement of symptoms after eradication [55] [56] [57] [58] [59] while others failed to show any such improvement [50, [60] [61] [62] . In 1998, four placebo-controlled randomised trials were reported in abstract form of which one showed improvement of symptoms after eradication treatment [63] , whereas the three others did not [64] [65] [66] . In the positive English MRC trial [63] , 21% of the patients that had re ceived eradication treatment were asymptomatic after one year, compared to 7 % who received placebo treatment. Al though this is statistically significant, the therapeutic gain was only 14%, and the 7% placebo rate found in this study is surprisingly low. If we compare these results with the Australian study [66] , we see that the placebo response rates after one year were similar, 21.8% versus 24.1%, after eradication treatment.
It has to be remembered that the Maastricht recommenda tions supporting eradication treatment in non-ulcer dyspep sia [7] contradict the NIH consensus [67] and the recom mendations of the British Society of Gastroenterology [68] .
A systematic review of various drug treatments in function al dyspepsia, summarising data for 3,978 patients from 52 trials, did not provide evidence of an effective treatment for NUD [69] .
Diagnosis of Helicobacter pylori Infection
Diagnosis of Helicobacter pylori infection can be made by invasive tests, requiring endoscopy (histology, cultures, PCR, rapid urease test) or non-invasive tests ( l3 C-urea breath-test, serology). These tests vary in sensitivity and specificity but most of them are highly accurate [70] (Ta ble 4).
The gold-standard for diagnosis of HP infection is endo scopic biopsy of the antral mucosa with histological confir mation of the organism's presence [71] . The CLO-test is the most widely used and studied rapid urease test with maximum sensitivity 24 hours after biopsy [72] . Serology is recommended for non-endoscopic screening. Commer cially available serological kits for HP infection show an overall sensitivity of 85% and a specificity of 79%, with no test being found to be more accurate than any other [73] . The performance of practice-based serological kits may need to be improved before recommending their gen eral use for screening. The urea breath-test is the best non- invasive test to determine eradication [74] . The major dis advantage of non-invasive tests compared to endoscopy is their lack of anatomical information about the presence of gastroduodenal ulceration.
Efficacy of Eradication Treatment
Eradication of Helicobacter pylori is the most clinicallyrelevant outcome of H. pylori treatment. Eradication treat ment should aim at an eradication rate of well over 80%.
It is now accepted that one should use a PPI-based triple therapy for seven days, using two antibiotics (clarithromy cin, amoxicillin, tetracycline or metronidazole) [75, 76] . A recent meta-analysis showed the superiority of combining two antibiotics, as opposed to one antibiotic alone, with acid-lowering therapy [77] . PPI (omeprazole) alone has been shown to reduce bacterial density in the antral muco sa, but does not eradicate H. pylori [78] . Pre-treatment with omeprazole alone resulted in substantially lower eradica tion rates (28%) [78] . Table 5 (consensus statement of the American College of Gastroenterology, 1996) gives a summary of the efficacy of different drug combinations and H. pylori cure rates [76] .
Within the context of a randomised trial, success rates for eradication therapy generally reflect efficacy. If good com pliance can be achieved, the effectiveness of the various H. pylori eradication regimens was 84% in an ongoing community-based study [79] . There is now evidence that eradicating HP in patients who present with a bleeding ul cer reduces the risk of rebleeding [80] [81] [82] [83] .
The Maastricht consensus report [75] , representing current European concepts in the management of HP infection, stated that eradication treatment is strongly recommended in the following situations: infected peptic ulcer patients including those in remission or receiving long-term anti-se cretory therapy, patients with bleeding peptic ulcer, lowgrade MALT lymphoma, gastritis with severe macro-or microscopic abnormalities, and following resection of gas tric cancer. MALT lymphomas often regress completely after eradication, rendering gastrectomy unnecessary [84] [85] [86] . Downloaded by: Bibliothèque Cantonale et Universitaire. Copyrighted material. Side-effects, usually mild, affect 10% of patients receiving triple therapy including bismuth [87] . Omeprazole-based triple therapy was better tolerated than bismuth-based ther apy in a randomised controlled trial [88] .
Recurrence after Eradication Treatment
Ulcer recurrence is significantly less common among H. pylori-cured patients versus uncured patients (6% vs. 67% for duodenal ulcer, 4% vs. 59% for gastric ulcer) [89] . The follow-up time in these studies ranged from six to 33 months. In a recently-published prospective longterm follow-up study [90] in non-NSAIDs users with endo scopically confirmed ulcer healing and eradicated H. py lori, no ulcer recurrence was detected over a period of up to 9.8 years.
Confirmation of the success of Helicobacter eradication is generally considered necessary in patients with persisting [80] or relapsing symptoms [87] after eradication therapy. Symptoms alone may not allow to distinguish between ul cer recurrence and reflux esophagitis as a substantial (10%) proportion of duodenal ulcer patients developed re flux esophagitis after H. pylori eradication [91] . Endoscopy therefore seems indicated in these cases. The annual re infection rate after successful eradication therapy is low (1.2%) [92] .
Impact of Endoscopy on Patient Outcome
There is only limited direct evidence of endoscopic impact on outcome in patients with dyspepsia; that is, studies comparing the outcome of patients with dyspeptic symp toms who either did or did not undergo diagnostic endos copy. Three studies merit discussion here. The first study [93] randomised dyspeptic patients to empirical H 2 -blocker therapy or endoscopy/upper GI series prior to prescription of H 2 -blockers. By the end of six months, H 2 -blocker use in both groups was similar (11 vs. 8.7%). Equal numbers of patients in each group were asymptomatic (42.5 vs. 39.5%). The second study [94] compared initial upper GI radiography to antacids and reassurance. After six months of follow-up, there were no significant differences in symptoms, disability, satisfaction or quality of life scores between the two groups. The third study [95] compared prompt endoscopy with H 2 -blocker therapy. In contrast to the two other studies, this trial [95] showed better outcome (less work loss, less drug use) and lower costs in the group randomised to prompt endoscopy. Two-thirds of the pa tients initially randomised to empirical treatment were fi nally endoscoped at one year. In all three studies, Helico bacter pylori infection was not assessed.
An alternative approach to establishing the efficacy of en doscopy in patients with dyspepsia is to examine popula tion trends. The first study [96] examined rates of peptic ulcer-related mortality, hospitalisation, surgery, physician visits, work loss and disability retirements in the US from 1977 to 1986. All these factors declined over time. The time-scale trends described were attributed to several fac tors, including the introduction of H 2 -blocker therapy, re duction in smoking and possible changes due to the in creasing use of endoscopy. The second study [97] retro spectively reviewed the use of endoscopy compared to pep tic ulcer mortality between 1979 and 1989. Although the utilisation of endoscopy rose from 21.7 to 25.6 procedures per thousand the mortality rate for peptic ulcer disease in creased by 4% in women while remaining stable in men. Death certification rates from peptic ulcer declined over the four decades in both sexes [98] . The main determinant of this is believed to be the introduction of H 2 -receptor an tagonists in the late 1970s, but other factors, such as ther apeutic endoscopy, may also have played a role. A popula tion-based study [99] dealing with diagnosis, treatment and prognosis of gastric cancer showed that endoscopy is pro gressively becoming the only viable diagnostic tool. These changes in diagnostic strategy were, however, associated with less remarkable trends in treatment and stage at diag nosis, thus failing to demonstrate an important contribution by endoscopy to improving outcome of gastric cancer. In summary, population studies and studies comparing out come before and after introduction of endoscopy have gen erally not shown conclusively that the introduction of en doscopy substantially affected patient outcome. 31], and that a "normal" result may substantially reduce work loss and medical care consumption [24] .
From a conceptual standpoint, endoscopy can be restricted to certain patients either based on the response to empirical therapy or based on criteria such as age, HP status, intake of NSAIDs or warning symptoms. Both approaches will be discussed briefly.
Decision to Endoscope Based on the Response to Empirical Therapy
In 1985, the American College of Physicians issued a prac tice guideline for dyspepsia [100] , which was also adopted some years later by the American Society for Gastrointes tinal Endoscopy [101] . Although not based on a clinical trial, this consensus statement recommended empirical anti-secretory therapy in all patients with uncomplicated dyspepsia, reserving a diagnostic upper GI endoscopy for those patients who did not respond to therapy or whose symptoms recurred on cessation of treatment. This recom mendation was based on observations that a precise anato mical diagnosis did not impact on the choice of treatment for most of the diseases associated with dyspeptic symp toms at that time. Furthermore, it was hoped that empirical treatment would improve case selection for organic diagno ses at endoscopy. The role of empirical treatment as a de cision tool for deciding on the use of endoscopy has been questioned. Bytzer [95] has shown that case selection of organic diagnoses is not reliably enhanced by empirical treatment as only 60 % of ulcer patients could be identified with this strategy. In addition, empirical therapy proved to be more expensive due to higher work loss and drug con sumption. Furthermore, empirical treatment postpones rather than eliminates the need for endoscopy [102] as dys peptic symptoms recur and two-thirds of patients rando mised to empirical treatment were thus finally endoscoped after one year [95] . Empirical treatment may also lead to an erroneous diagnosis of functional dyspepsia in patients with endoscopic lesions who have not experienced symp tom relief but have undergone complete healing of the le sion (e.g. ulcer) because the relationship between symp toms and ulcer healing is not conclusive [102] . Empirical therapy therefore proved to be a weak selection criterion for endoscopy.
Decision to Endoscope Based on Specific Patient-Related Characteristics
Sobala [19] assessed a policy of screening dyspeptic pa tients before endoscopy using a strategy based on Helico bacter status and use of non-steroidal anti-inflammatory drugs. He used three criteria to identify patients expected to show a low yield from diagnostic endoscopy: 1) age <45 years; 2) negative H. pylori test, and 3) no history of NSAIDs use. The screening criteria were applied retrospec tively in 842 patients with known histological H. pylori sta tus, and prospectively to 293 patients referred for diagnos tic endoscopy. Overall, this screening strategy would have reduced endoscopy workload by 23.3% and would have had a sensitivity rate for detection of peptic ulcer of 97.4%. No peptic ulcer or malignant disease was missed in the patients studied prospectively, but six out of 192 peptic ulcers in the histology (i.e., retrospective) group would have been missed. In another study [103] , 52 sub jects aged 45 or less were screened by HP serology. All 27 who were sero-negative had no ulcer disease while sev en out of 25 sero-positive patients had ulcer disease. Screening would have avoided 35% of endoscopies in these patients while missing 13% of patients with endo scopic findings (esophagitis and gastritis). In a further study [18] , 183 dyspeptic patients aged <45 were screened by a history-taking of sinister symptoms and regular use of NSAIDs, together with serological testing for H. pylori. Endoscopy was performed in 113 patients, of whom 90 were sero-positive, 14 had sinister symptoms, and nine had used NSAIDs regularly. The remaining 70 patients who were H. pylori sero-negative had no sinister symptoms and had not taken NSAIDs, did not undergo endoscopy but received symptomatic treatment. Of these patients, only three were re-referred after screening for endoscopy. Thus. 67 (37%) endoscopies were avoided. When the non-endoscoped screening-negative patients were compared with the cohort of endoscoped screening-negative patients, there was no difference between the groups in terms of symptom severity. Medication use was, however, significantly less in those patients who did not undergo endoscopy [18] . This study indicates that a screening based on H. pylori serolo gy, a history of sinister symptoms (e. g. weight loss, hemor rhage) or a history of NSAIDs use was beneficial in dys peptic patients. Thirty-seven percent of endoscopies were avoided, and drug usage was reduced without disadvanta ging those patients not endoscoped.
The above-mentioned studies all took place in patients re ferred for endoscopy. Two randomized studies, published as abstracts in 1998, prospectively compared a "test and treat" strategy (i.e., H. pylori-positive patients with dyspep sia received eradication therapy without endoscopy) with prompt endoscopy in primary care. In the first study [104] which included 500 patients, no difference between the two groups was found with respect to rate of symptom-free days, severity of symptoms or number of sick leave days after one year follow-up. However, the prompt endoscopy group resulted in higher patient satisfaction whereas the "test and treat" group was, not surprisingly, associated with a significant (63 %) reduction in endoscopic work load. Pa tients with alarm symptoms were excluded from the study, and patients taking NSAIDs were automatically endos coped. The cost-effectiveness of a "test and treat" strategy, compared to prompt endoscopy, was confirmed in another randomized controlled trial [105] . However, none of these studies directly compared a "test and treat" strategy with a "test and scope" strategy (i. e., H. pylori-positive patients with dyspepsia are routinely endoscoped) in primary care. This might yield different results, in as much that the cost advantage of a "test and treat" strategy may be less evident Downloaded by: Bibliothèque Cantonale et Universitaire. Copyrighted material. and the problem of overtreatment with eradication therapy (see below) would be avoided.
The question of whether patients testing positive for Heli cobacter pylori should be endoscoped ("test and scope") or treated ("test and treat") continues to be hotly debated, with indirect evidence coming from several decision analy ses. The first decision analysis [106] in HP-positive pa tients with dyspepsia concluded that initial anti-H. pylori therapy is the most cost-effective management strategy. Results were not substantially affected by varying the de gree of H. pylori eradication, by the side-effects of antibio tics, or the range of symptoms in curing H. pylori infec tion. Endoscopy-related costs would need to be reduced by 96% before the two strategies become equally cost-ef fective. Another decision analysis [107] concluded that era dication treatment is less costly than H 2 -blocker therapy in patients under 45 years of age with dyspepsia. The model in this study used endoscopy to identify appropriate pa tients to receive eradication treatment (patients with ulcer disease). When the initial cost of identifying appropriate patients for eradication treatment is added to the analysis, the cost savings of eradication treatment take almost eight years to accrue. Similar results were obtained in a third de cision analysis [108] . A further decision analysis came to a different result. Direct medical charges in the first year after the onset of dyspepsia were compared between three strategies: prompt endoscopy, empirical therapy (^-block ers) or testing for H. pylori [109] . Medical charges were-2162 US dollars for prompt endoscopy and 2122 US dol lars for empirical therapy. Initial non-invasive testing for H. pylori cost less than prompt endoscopy if H. pylori-posi tive patients with dyspepsia received antimicrobial therapy without endoscopy (that is, "test and treat" strategy) but would have cost more if patients with H. pylori were routi nely endoscoped ("test and scope" strategy). The authors concluded that the choice of the optimal management strat egy was a "toss-up". Only very modest savings may result from practice guidelines that recommend empirical anti-HP therapy in the management of patients with dyspepsia. At the present time, randomized studies directly comparing the "test and scope" and the "test and treat" strategies in primary care are needed to evaluate outcome and patient preferences. The value of each strategy will depend on the prevalence of H. pylori (low prevalence allowing more sav ings than high prevalence in the "test and scope" strategy), the still unproved impact of HP eradication therapy on out come in documented non-ulcer dyspepsia, patient and doc tor preferences, and the cost of endoscopy (very variable according to the country). As the cost of upper GI endos copy differs greatly between the United States (> 1000 US dollars) and Europe, cost-effectiveness of upper GI endos copy must be judged differently. Thus, endoscopy may be cost competitive if its cost is 200-500 US dollars [110] , which is the case in most European countries. The follow ing table briefly summarises the pros and cons of the "test and scope" (Table 6 ) and the "test and treat" ( Table 7) strategies:
In conclusion, the question of whether "test and scope" or "test and treat" should be the preferred management strat egy remains open. Taking into account the uncertain effi cacy of eradication treatment in non-ulcer dyspepsia with the huge risk of "overtreatment" in a test and treat strategy, the lower cost of endoscopy in Europe, current state of knowledge and all the pros and cons stated above, a "test and scope" strategy seems, at the present time, preferable. However, uncertainty will make this question one of the most prominent to be debated.
Surveillance Endoscopy in Patients with Known Ulcer Disease
It has become standard practice to follow gastric, but not duodenal ulcers endoscopically up to healing, because of concerns that gastric ulcers may represent early gastric ma lignancy. Diagnosis of gastric cancer in apparently benign Downloaded by: Bibliothèque Cantonale et Universitaire. Copyrighted material.
gastric ulcers has been reported in 1 to 6 % of patients with gastric ulcer [111] [112] [113] . Bytzer et al. evaluated the bene fits of routine endoscopic follow-up of gastric ulcer to de tect malignancy. They found that each curable gastric can cer was found at the expense of approximately 250 followup endoscopies [114] . To our knowledge, there has been no randomized controlled trial or prospective study comparing outcome for patients with and without endoscopic followup of gastric ulcer to healing. Two retrospective studies re viewed the clinical course in patients diagnosed with gas tric ulcer. The first study [115] reviewed 148 gastric ulcers followed up by serial endoscopy over a 5-year period. One hundred and seven patients were followed to healing and 41 cases did not heal. The average number of endoscopies per case was 2.7. Of 67 gastric cancers diagnosed during the same time period, 62 were suspected of being malig nant by their macroscopic appearance and only one cancer was missed after biopsy and/or brush cytology. The authors estimate that favoring a policy of single endoscopy without follow-up when all signs indicate a benign ulcer would re sult in significant cost savings, as compared to the practice of routine follow-up endoscopy. Another study [111] looked at the impact of gastric ulcer surveillance to detect gastric carcinoma after surgery. Patients with macroscopically and histologically benign gastric ulcer were asked to return after four weeks of therapy. Of 142 patients with an initial diagnosis of benign gastric ulcer, 1.8% had malig nancy documented on repeat examination. Follow-up ex aminations did not, however, result in significant differen ces in 5-year survival rates. A large population-based longterm cohort study [116] in hospitalised patients with gas tric or duodenal ulcers found that the risk of gastric cancer was almost twice the expected rate in patients with gastric ulcers, whereas the risk was less in patients with duodenal ulcers. The authors conclude that gastric ulcer disease and gastric cancer have etiological factors in common.
Dyspepsia in Patients Taking NSAIDs
Prevalence of NSAID-Induced Gastro-Duodenal Disease
The use of NSAIDs in the general population is extremely frequent. In a population-based study in the USA, age-and gender-adjusted annual prevalence rates for aspirin and non-aspirin NSAIDs use in the elderly were 60% and 26% respectively [117] . . A third trial even showed that eradication treatment was associated with re duced ulcer healing [131] . In conclusion, eradication of HP in chronic NSAID users is probably not justified.
Prophylaxis of NSAID-Induced Ulcers
A large meta-analysis on the prevention of NSAID-induced mucosal injury in 4,325 patients [132] concluded that mi soprostol, but not H 2 -blockers, reduced the risk of gastric ulcers. It was also found that both misoprostol and H 2blockers prevented duodenal ulcer in long-term NSAIDsusers. These findings were confirmed in other randomised controlled trials [133] [134] [135] . Misoprostol was also shown to significantly reduce serious NSAID-induced upper gastro intestinal complications such as perforation, gastric outlet obstruction and bleeding. These results were obtained in large, well-conducted, randomised trials in 8,843 patients with chronic rheumatoid arthritis [134] . However, miso prostol is often associated with side-effects such as diar rhea and abdominal cramps [136] . The prophylactic effect of omeprazole in NSAIDs users was recently assessed in a placebo-controlled, randomised study [136] . During a 3month study period, 4.7% of omeprazole-treated patients developed duodenal or gastric ulcers, compared with 16.7% of placebo-treated patients. In addition, the devel opment of dyspeptic symptoms was also significantly re duced with omeprazol, compared to placebo. Downloaded by: Bibliothèque Cantonale et Universitaire. Copyrighted material.
In a double-blind randomized study published in 1998 [137] , omeprazole healed and prevented ulcers more effec tively than did ranitidine in NSAIDs users. Another dou ble-blind randomized trial comparing omeprazole 20 mg, 40 mg or misoprostol 800 mg daily found that the overall healing rates of ulcers and symptoms were similar for the three treatment regimens. However, omeprazole was better tolerated and associated with a lower rate of relapse during maintenance treatment than misoprostol [138] .
Impact of Endoscopy in NSAIDs Users
There are to our knowledge no studies comparing outcome of patients with uncomplicated NSAID-induced peptic dis ease with and without endoscopy.
Stress Ulcer
Although endoscopic studies have demonstrated gross mu cosal injury within hours of a stressful event in nearly 100% of patients examined, most stress ulcers heal when normal gastric defence mechanisms are restored. In a ran domised controlled trial [139] , 80% of patients requiring aortic surgery developed stress ulcers post-operatively. A rigorously-conducted meta-analysis published recently [140] , and including 63 randomised trials in 7,218 patients, addressed ulcer prophylaxis in critically-ill adult patients. Sucralfate was associated with a lower morbidity rate com pared with antacids and a trend towards lower mortality when compared with H 2 -receptor antagonists. However, none of the three treatments studied (sucralfate, ^-recep tor antagonists, NSAIDs) revealed a significant effect on mortality rate. Stress-ulcer bleeding is rare (1-1.5%) [141, 142] . Sucralfate significantly decreased overt bleed ing in comparison with both placebo and NSAIDs. For clinically-important bleeding, H 2 -receptor antagonists re mained superior to placebo.
The role of PPI in stress ulcer prophylaxis has been studied in a recent randomized trial. Sixty-seven high-risk patients were randomized to receive either ranitidine 150mg or omeprazole 40 mg per day [143] . Eleven patients in the ra nitidine and two patients in the omeprazole group devel oped clinically important bleeding (p<0.05). Despite its potent acid inhibition, nosocomial pneumonia was seen in one patient only under omeprazole, compared to 5 patients receiving ranitidine. Further studies are needed to deter mine the role of PPI in stress ulcer prophylaxis [144] .
Only a small proportion of patients presenting with com plications such as gastrointestinal hemorrhage or perfora tion, require medical and/or surgical intervention [145] . The role of endoscopy in bleeding stress ulcers is discussed in a separate publication (upper gastrointestinal bleeding and other alarm symptoms) [146] .
Complicated Peptic Ulcer Disease
Hemorrhage as a complication of ulcer disease has been dealt with in a separate publication [146] . The epidemiolo gy of peptic ulcer perforation has evolved over the past 50 years: incidence has decreased except in women over 65 years of age, and there has been an increase in mean age at time of perforation and a decrease of the male:female ratio [147] . The short-term mortality of peptic ulcer dis ease has fallen from 1952 to 1990 [148] . Uncertainty re mains about the role of Helicobacter pylori in the patho genesis of ulcer perforation since 50% of patients with perforation seem to be HP-negative [147] . The single most important risk factor associated with both ulcer perforation and ulcer bleeding is the increasing use of NSAIDs [147] . The localisation of perforation has also changed over time, with perforation now being more frequently encountered in the pyloric and prepyloric area than in the duodenum [149] .
Gastric Cancer
Prevalence, Incidence and Risk Factors of Gastric Cancer
The prevalence of gastric cancer in dyspeptic patients in Europe is in the order of 1-2%. In three recent prospec tive studies [17, 20, 21] , two gastric cancers were found in 2,598 dyspeptic patients under 40 years of age (0.8 %o), vs. 88 cases in 4,843 patients over 40 to 45 years (1.8%), showing a striking higher-age predominance with gastric cancer being very rare in young dyspeptic patients.
Fifty years ago, stomach cancer was the leading cause of death from cancer in males in the USA. Since then, mortal ity and incidence have decreased virtually everywhere.
There is a band of high-and above-average incidence from Central Italy to the Swiss border, continuing through Ba varia up to the Danish border, while the south of Italy, Great Britain and most of France are either average or be low-average [150, 151] . These trends are believed to be due to changes in food preparation and storage, and differences in consumption of fruit and vegetables. Classical risk con ditions for gastric cancer are the following [152]: chronic atrophic gastritis and intestinal metaplasia, pernicious ane mia, partial gastrectomy for benign disease, Helicobacter pylori infection, Menetrier's Disease, gastric adenomatous polyps. Genetic and environmental factors include a family history of gastric cancer, low consumption of fruit and vegetables, consumption of salted smoked foods, cigarette smoking, low social and economic status, and blood type A.
Helicobacter pylori was declared a Class I carcinogen in June 1994 (World Health Organisation). Available evidence on the relationship between Helicobacter pylori and gastric cancer was assessed in a 1996 consensus statement [153] . HP is the major cause of multifocal atrophic gastritis and is also believed to lead to the development of intestinal meta plasia [98] , while chronic gastritis is clearly not associated with any increased risk of cancer [153] . The Eurogast Downloaded by: Bibliothèque Cantonale et Universitaire. Copyrighted material.
Study Group [41] , a prospective epidemiological study in over 3,000 subjects of 14 populations in Europe, USA and Japan, found a six-fold increased risk of gastric cancer in populations with 100 % HP infection compared with popu lations without infection. The hypothesis that HP infection is a risk factor for gastric cancer is further endorsed by three large case-controlled studies [154] [155] [156] . Most per sons infected with HP will, however, never develop a gas tric carcinoma and other factors that increase the risk of carcinoma among persons infected with HP therefore need to be identified [156] . Early-life infection by Helicobacter pylori increases the risk of developing both gastric cancer and gastric ulcers [157] .
Helicobacter pylori infection is invariably associated with the presence of lymphoid follicles which are precursors of MALT lymphomas [153] . There is evidence that the suc cessful cure of Helicobacter pylori infection results in the regression, and perhaps even the cure, of MALT lymphoma in 50-75% of patients [84] .
Symptoms of Gastric Cancer
Although gastric cancer is a matter of concern for clini cians evaluating patients with dyspepsia, most patients with gastric cancer do not develop symptoms or signs until the disease is no longer curable. Superficial and surgically cur able gastric carcinoma typically produce no symptoms [152] . In a prospective series of 720 patients with gastric carcinoma, only 8% were eligible for curative resection [158] . In a large review performed by the American Col lege of Surgeons [152], weight loss (62%) and abdominal pain (52%) were the most frequent symptoms at the time of initial diagnosis. About 10% of all gastric cancer pa tients present with hematemesis or melena, and patients presenting with bleeding rarely have early cancers [159] .
Histological Issues in Gastric Cancer
Differences in diagnostic criteria for gastric carcinoma be tween Japanese and Western pathologists may contribute to the relatively high incidence and good prognosis of gastric cancer in Japan. Thus, in Japan, gastric carcinoma is diag nosed on nuclear and structural criteria even when invasion is absent according to the Western viewpoint [160] . In a prospective, multi-center study, it was found that gastric cancer was associated with 36% of moderate and with 80% of severe gastric epithelial dysplasia; the follow-up of patients with dysplasia considerably enhances the chan ces of diagnosing gastric cancer in its early stages [161] . In these patients, a repeat endoscopy every three months is re commended in presence of moderate dysplasia with im mediate control endoscopy and multiple biopsies in the presence of severe dysplasia.
Impact of Endoscopy on Detection Rate
There have been important changes in the diagnostic strat egy for gastric cancer, endoscopy being now the most fre quently-used diagnostic tool [99] . The proportion of resec tions for cure increased from 38 to 50%, as did the propor tion of cases confined to the gastric wall (6-12%). The in vestigation of dyspeptic patients over 40 years of age after their first consultation with the general practitioner could increase the proportion of early gastric cancers detected to 26% and the proportion of operable cases to 63% [162] . The most obvious trends in the management of gastric can cer come from the reduction of operative mortality rate. Endoscopic surveillance in post-gastrectomy patients, aim ing at detecting early gastric-stump cancer, does not seem to reduce mortality [163] , and the risk of developing gas tric cancer in these patients does not seem to be enhanced as compared to the general population [164] . Endoscopic ultrasound has been shown to better assess T and N cate gories pre-operatively than computed tomography or interoperative surgical assessment [165] [166] [167] .
Panel Results
Considering the above review of relevant literature, the pa nel evaluated 192 specific theoretical patient scenarios related to the use of gastrointestinal endoscopy in patients with dyspepsia.
Definition of Terms
All terms and definitions were reviewed and approved by the panelists before proceeding to ratings of clinical indica tions; they are listed in Table 8 .
Clinical Variables
The clinical variables used to describe the list of indica tions related to dyspepsia are shown in Table 9 . The main variable used to structure the list of indications for dyspep sia was the parameter of previous investigations, resulting in four main sub-categories. 
General Panel Results
Uncomplicated dyspepsia
Dyspepsia without alarm symptoms. (Hematemesis, melena, esophageal dysphagia, unexplained weight loss, iron-deficiency anemia are dealt with in the article on alarm symptoms [146] .
Episode of dyspepsia
Minimum duration to be considered as one episode: 4 weeks. Time interval for the definition of the onset of a new episode: 1 month free of symptoms without treatment.
Eradication treatment for Helicobacter pylori infection
Treatment regimen composed of two antibiotics and an PPI/H2 blocker with an eradication rate supposed to exceed 90%.
Helicobacter test
According to the situation, either a non-endoscopic test (serology, C13 breath-test), or an endoscopic test (urease test, histology, culture).
Empirical acid-lowering treatment
In order to serve as a decisional tool for the panel, the minimum duration of treatment is > 1 week of continuous intake. 
NSAIDs intake
Continuous intake of NSAIDs for >3 days, or intermittent intake of NSAIDs at onset of symptoms at least every 2 days for at least 1 week
Previous investigations
A previous investigation by either an UGI endoscopy or UGI series performed within 2 years of the present episode of dyspepsia.
be similar in each case. Appropriateness is defined in a se parate publication in this issue of the Journal [1] .
Specific Clinical Panel Results
Description of Appropriateness
The main results related to appropriateness are worded as an overall statement ( Table 10 ) encompassing several clini cal scenarios (clustering). In some cases, the same scenario may apply to more than one statement. One hundred and sixty-seven of the 192 indications (94%) could be charac terized by the eight overall statements given below. Detailed appropriateness and necessity criteria encompassing all 192 indications are available in a computerized form accessible via Internet (http://www.epage.ch).
In HP-positive patients with persisting symptoms and not having received eradication treatment, we assessed whether panelists would favor a "test-and-scope" strategy (i.e., en doscope dyspeptic patients testing positive for H. pylori) or a "test-and-treat" strategy (i. e., treat dyspeptic patients em pirically if testing positive). Sixteen scenarios pertain to this situation. In patients >45 years of age, the "test-andscope" strategy was favored unless previous investigations showed duodenal or prepyloric ulcer or duodenitis. In the presence of a previous history of gastric ulcer, the "testand-scope" strategy was always preferred. The "test-andtreat strategy" was preferred if previous investigations had shown duodenal or prepyloric ulcer or duodenitis, or in pa tients <45 years of age in whom previous UGE or UGI series were normal. In individuals with uncomplicated dyspeptic symptoms that resolved with or without treatment, indication for gastrointestinal endoscopy is generally inappropriate with the exception of some scenarios related to patients > 45 years old with previous gastric ulcer (uncertain)
In individuals with persistent dyspepsia, and with a previous history of gastric ulcer, indication for gastrointestinal endoscopy is appropriate In individuals aged 45 and over with persistent dyspepsia, and without any previous investigations or with unknown results of previous investigations, indication for gastrointestinal endoscopy is appropriate
In individuals aged 45 and over with persistent dyspepsia, and normal results of previous investigations of similar symptoms, indication for gastrointestinal endoscopy is generally uncertain unless symptoms persist after HP eradication has been given in a HP-positive patient (appropriate) In individuals aged 45 and over with persistent dyspepsia, and previous investigations showing duodenal ulcer, prepyloric ulcer or duodenitis, indication for gastrointestinal endoscopy is generally uncertain unless empiric acid lowering treatment has been given and HP test is negative (appropriate) unless symptoms persist after HP eradication has been given in a HP-positive patient (appropriate)
In individuals aged less than 45 with persistent dyspepsia, and without any previous investigations or with unknown results of previous investigations, indication for gastrointestinal endoscopy is generally uncertain unless HP test is unknown and no empirical acid-lowering treat ment has been given (inappropriate) unless symptoms persist after HP eradication has been given in a HP-positive patient (appropriate)
In individuals aged less than 45 with persistent dyspepsia, and normal results of previous investigations of similar symptoms, indication for gastrointestinal endoscopy is inappropriate unless symptoms persist after HP eradication has been given in a HP-positive patient (uncertain)
In individuals aged less than 45 with persistent dyspepsia, and previous investigations showing duodenal ulcer, prepyloric ulcer or duodenitis, indication for gastrointestinal endoscopy is inappropriate unless empirical acid lowering treatment has been given and HP status is negative or unknown (uncertain) unless symptoms persist after HP eradication has been given in a HP-positive patient (appropriate)
Description of Necessity
Twelve out of 192 scenarios (6.3%) were judged necessary. All necessary indications (Table 11 ) in uncomplicated dys pepsia pertained to patients > 45 years of age. Necessity is defined in a joint publication in this issue of the Journal [1] .
Conclusions
The current literature underlines the frequent occurrence of dyspepsia in clinical practice and the wide variations in diagnosis and treatment. The advent of Helicobacter pylori as well as the need for cost containment in almost all de veloped countries have had a profound impact on diagnos tic and therapeutic strategies in dyspepsia which are cur rently hotly debated and widely assessed. The literature suggests that UGE should be used in patients with a rea sonably high probability of a clinically relevant diagnosis such as ulcer disease or cancer.
One third of EPAGE criteria related to dyspepsia. EPAGE criteria judged performance of UGE often inappropriate (59%) in uncomplicated dyspepsia. Very few situations (6%) were judged necessary. Six clinical and circumstan tial parameters permitted detailed assessment of all possi ble scenarios: patient age, NSAIDs intake, Helicobacter status, results of previous UGE or UGI series, whether or not empirical antisecretory treatment was given and the clinical response to this treatment. Although highly de tailed and specific, 94% of the scenarios could be encom passed in simple, descriptive statements applicable to clin ical practice. However, the full potential and utility of these criteria will become apparent on the computerised version accessible via Internet (http://www.epage.ch) that will per mit easy application of all scenarios even in the most com plex situations.
